QN-019a by Hangzhou Qihan Biotechnology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

QN-019a is under clinical development by Hangzhou Qihan Biotechnology and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase I drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QN-019a’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

QN-019a overview

QN-019a is under development for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The therapeutic candidate (CAR-NK) comprises allogeneic genetically modified NK cells expressing chimeric antigen receptors (CAR) targeting cells expressing B lymphocyte antigen CD19.

Hangzhou Qihan Biotechnology overview

Hangzhou Qihan Biotechnology is a healthcare company. The company develops gene-editing organ transplantation technology.

For a complete picture of QN-019a’s drug-specific PTSR and LoA scores, buy the report here.